Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAF(V600E) patient-derived papillary thyroid carcinoma preclinical model

BRAF(V600E) mutation exerts an essential oncogenic function in many tumors, including papillary thyroid carcinoma (PTC). Although BRAF(V600E) inhibitors are available, lack of response has been frequently observed. To study the mechanism underlying intrinsic resistance to the mutant BRAF(V600E) sele...

Descripción completa

Detalles Bibliográficos
Autores principales: Duquette, Mark, Sadow, Peter M., Husain, Amjad, Sims, Jennifer N., Antonello, Zeus A., Fischer, Andrew H., Song, Chen, Castellanos-Rizaldos, Elena, Makrigiorgos, G. Mike, Kurebayashi, Junichi, Nose, Vania, Van Hummelen, Paul, Bronson, Roderick T., Vinco, Michelle, Giordano, Thomas J., Dias-Santagata, Dora, Pandolfi, Pier Paolo, Nucera, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767444/
https://www.ncbi.nlm.nih.gov/pubmed/26636651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767444/
https://www.ncbi.nlm.nih.gov/pubmed/26636651

Ejemplares similares